Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.
Allinaire Therapeutics has raised $700K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2026.
Allinaire Therapeutics's investors include BioCrossroads, IU Ventures, BioMotiv.
Allinaire Therapeutics is headquartered in Cleveland, United States.
Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.
Allinaire Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allinaire Therapeutics — Funding & Investors." VCBacked, April 14, 2026, https://www.vcbacked.co/company/allinaire-therapeutics. Accessed August 17, 2026.
VCBacked. (2026). Allinaire Therapeutics — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/allinaire-therapeutics
{{cite web |title=Allinaire Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/allinaire-therapeutics |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated